Foundational AI models and compute for designing biomolecules
Boltz (Boltz PBC) builds frontier biomolecular models and high-performance compute for designing proteins and small molecules. Its product line includes Boltz API and Boltz Lab/platform tools for structure prediction, binding-affinity work, small-molecule hit discovery, and protein design, alongside open-source models such as Boltz-2 and BoltzGen. The company reports millions of downloads and adoption across research and pharma. In October 2026 NVIDIA highlighted Boltz among UK AI startups receiving ecosystem investment for drug discovery.